Tokyo Tape
Sign in
← Immuno-Biological Laboratories

Annual report

4570.TEDINET S100OIQD
Period2021-04-01 → 2022-03-31
Filed2022-06-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
MetricValuePeriodScopeSource row
Revenue¥648m2021-04-01 → 2022-03-31Cons.Net sales
Revenue¥603m2020-04-01 → 2021-03-31Cons.Net sales
Revenue¥577m2019-04-01 → 2020-03-31dCons.Net sales (5-year summary)
Revenue¥781m2018-04-01 → 2019-03-31dCons.Net sales (5-year summary)
Revenue¥758m2017-04-01 → 2018-03-31dCons.Net sales (5-year summary)
Operating income−¥122m2021-04-01 → 2022-03-31Cons.Operating income
Operating income−¥241m2020-04-01 → 2021-03-31Cons.Operating income
Ordinary income−¥243m2021-04-01 → 2022-03-31Cons.Ordinary income
Ordinary income−¥311m2020-04-01 → 2021-03-31Cons.Ordinary income
Ordinary income−¥679m2019-04-01 → 2020-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥156m2018-04-01 → 2019-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥49m2017-04-01 → 2018-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥250m2021-04-01 → 2022-03-31Cons.Income before income taxes
Profit before tax−¥311m2020-04-01 → 2021-03-31Cons.Income before income taxes
Net income (owners)−¥259m2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥319m2020-04-01 → 2021-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥668m2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥167m2018-04-01 → 2019-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥53m2017-04-01 → 2018-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥259m2021-04-01 → 2022-03-31Cons.Profit loss
Net income−¥319m2020-04-01 → 2021-03-31Cons.Profit loss
Total assets¥1.7bnat 2022-03-31Cons.Assets
Total assets¥1.8bnat 2021-03-31Cons.Assets
Total assets¥2.4bnat 2020-03-31dCons.Total assets (5-year summary)
Total assets¥3.0bnat 2019-03-31dCons.Total assets (5-year summary)
Total assets¥3.3bnat 2018-03-31dCons.Total assets (5-year summary)
Total liabilities¥337mat 2022-03-31Cons.Liabilities
Total liabilities¥209mat 2021-03-31Cons.Liabilities
Net assets / equity¥1.4bnat 2022-03-31Cons.Net assets
Net assets / equity¥1.6bnat 2021-03-31Cons.Net assets
Net assets / equity¥1.9bnat 2020-03-31dCons.Net assets
Net assets / equity¥2.1bnat 2019-03-31dCons.Net assets (5-year summary)
Net assets / equity¥2.0bnat 2018-03-31dCons.Net assets (5-year summary)
Cash and deposits¥508mat 2022-03-31Cons.Cash and deposits
Cash and deposits¥604mat 2021-03-31Cons.Cash and deposits
Cash & equivalents¥449mat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥552mat 2021-03-31Cons.Cash and cash equivalents
Cash & equivalents¥974mat 2020-03-31dCons.Cash and cash equivalents
Cash & equivalents¥1.5bnat 2019-03-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥2.5bnat 2018-03-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥93m2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥194m2020-04-01 → 2021-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥609m2019-04-01 → 2020-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥244m2018-04-01 → 2019-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥74m2017-04-01 → 2018-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥156m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥17m2020-04-01 → 2021-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥11m2019-04-01 → 2020-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥593m2018-04-01 → 2019-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥6m2017-04-01 → 2018-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥144m2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥216m2020-04-01 → 2021-03-31Cons.Net cash provided by used in financing activities
Financing cash flow¥81m2019-04-01 → 2020-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥126m2018-04-01 → 2019-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥138m2017-04-01 → 2018-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-27.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-34.232020-04-01 → 2021-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-762019-04-01 → 2020-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-19.822018-04-01 → 2019-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-7.012017-04-01 → 2018-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥146.92at 2022-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥174.7at 2021-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥208.97at 2020-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥245.47at 2019-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥241.64at 2018-03-31dCons.Net assets per share (5-year summary)
Equity ratio80.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio88.5%at 2021-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio82.0%at 2020-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio71.7%at 2019-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio61.1%at 2018-03-31dCons.Equity to asset ratio (5-year summary)
Employees63at 2022-03-31Cons.Number of employees
Employees65at 2021-03-31Cons.Number of employees
Employees65at 2020-03-31dCons.Number of employees
Employees61at 2019-03-31dCons.Number of employees
Employees57at 2018-03-31dCons.Number of employees
Revenue¥604m2021-04-01 → 2022-03-31StandaloneNet sales
Revenue¥532m2020-04-01 → 2021-03-31StandaloneNet sales
Revenue¥500m2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Revenue¥631m2018-04-01 → 2019-03-31dStandaloneNet sales (5-year summary)
Revenue¥643m2017-04-01 → 2018-03-31dStandaloneNet sales (5-year summary)
Operating income−¥103m2021-04-01 → 2022-03-31StandaloneOperating income
Operating income−¥217m2020-04-01 → 2021-03-31StandaloneOperating income
Ordinary income−¥70m2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income−¥197m2020-04-01 → 2021-03-31StandaloneOrdinary income
Ordinary income−¥503m2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥160m2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥48m2017-04-01 → 2018-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥116m2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Profit before tax−¥212m2020-04-01 → 2021-03-31StandaloneIncome before income taxes
Net income−¥124m2021-04-01 → 2022-03-31StandaloneProfit loss
Net income−¥219m2020-04-01 → 2021-03-31StandaloneProfit loss
Net income−¥547m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income−¥179m2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Net income−¥64m2017-04-01 → 2018-03-31dStandaloneNet income loss (5-year summary)
Total assets¥2.0bnat 2022-03-31StandaloneAssets
Total assets¥2.0bnat 2021-03-31StandaloneAssets
Total assets¥2.4bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥2.9bnat 2019-03-31dStandaloneTotal assets (5-year summary)
Total assets¥3.2bnat 2018-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥279mat 2022-03-31StandaloneLiabilities
Total liabilities¥118mat 2021-03-31StandaloneLiabilities
Net assets / equity¥1.7bnat 2022-03-31StandaloneNet assets
Net assets / equity¥1.8bnat 2021-03-31StandaloneNet assets
Net assets / equity¥2.1bnat 2020-03-31dStandaloneNet assets
Net assets / equity¥2.1bnat 2019-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.0bnat 2018-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥495mat 2022-03-31StandaloneCash and deposits
Cash and deposits¥535mat 2021-03-31StandaloneCash and deposits
EPS (basic)¥-13.272021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-23.522020-04-01 → 2021-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-62.242019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-21.212018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-8.512017-04-01 → 2018-03-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥184.61at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥197.88at 2021-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥221.41at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥244.88at 2019-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥240.37at 2018-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio86.1%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio93.9%at 2021-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.5%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio73.4%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio61.8%at 2018-03-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued9,314,590at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,314,590at 2021-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,314,590at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued8,724,590at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued8,333,090at 2018-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees62at 2022-03-31StandaloneNumber of employees
Employees58at 2021-03-31StandaloneNumber of employees
Employees56at 2020-03-31dStandaloneNumber of employees
Employees52at 2019-03-31dStandaloneNumber of employees
Employees48at 2018-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 42
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2021-04-01 → 2022-03-31−¥3m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2022-03-31−¥3m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2022-03-31¥560,000
Cosmeticsreportable segmentrevenue2021-04-01 → 2022-03-31¥13m
Cosmeticsreportable segmentrevenue external2021-04-01 → 2022-03-31¥13m
Cosmeticsreportable segmentsegment assetsat 2022-03-31¥93m
Cosmeticsreportable segmentsegment profit2021-04-01 → 2022-03-31−¥13m
Gene Recombination Silkworm Developmentreportable segmentsegment assetsat 2022-03-31¥453m
Gene Recombination Silkworm Developmentreportable segmentsegment profit2021-04-01 → 2022-03-31−¥95m
Immunity Relatedreportable segmentrevenue2021-04-01 → 2022-03-31¥637m
Immunity Relatedreportable segmentrevenue external2021-04-01 → 2022-03-31¥634m
Immunity Relatedreportable segmentrevenue intersegment2021-04-01 → 2022-03-31¥3m
Immunity Relatedreportable segmentsegment assetsat 2022-03-31¥1.2bn
Immunity Relatedreportable segmentsegment profit2021-04-01 → 2022-03-31−¥15m
—segment totalemployeesat 2022-03-3163 pure
—segment totalrevenue2021-04-01 → 2022-03-31¥651m
—segment totalrevenue external2021-04-01 → 2022-03-31¥648m
—segment totalrevenue intersegment2021-04-01 → 2022-03-31¥3m
—segment totalsegment assetsat 2022-03-31¥1.7bn
—segment totalsegment profit2021-04-01 → 2022-03-31−¥123m
Reconciling Itemsreconcilingrevenue2020-04-01 → 2021-03-31−¥17m
Reconciling Itemsreconcilingrevenue intersegment2020-04-01 → 2021-03-31−¥17m
Reconciling Itemsreconcilingsegment profit2020-04-01 → 2021-03-31¥960,000
Cosmeticsreportable segmentrevenue2020-04-01 → 2021-03-31¥14m
Cosmeticsreportable segmentrevenue external2020-04-01 → 2021-03-31¥14m
Cosmeticsreportable segmentsegment assetsat 2021-03-31¥55m
Cosmeticsreportable segmentsegment profit2020-04-01 → 2021-03-31−¥14m
Gene Recombination Silkworm Developmentreportable segmentsegment assetsat 2021-03-31¥565m
Gene Recombination Silkworm Developmentreportable segmentsegment profit2020-04-01 → 2021-03-31−¥173m
Immunity Relatedreportable segmentcapex2020-04-01 → 2021-03-31¥13m
Immunity Relatedreportable segmentrevenue2020-04-01 → 2021-03-31¥605m
Immunity Relatedreportable segmentrevenue external2020-04-01 → 2021-03-31¥589m
Immunity Relatedreportable segmentrevenue intersegment2020-04-01 → 2021-03-31¥17m
Immunity Relatedreportable segmentsegment assetsat 2021-03-31¥1.2bn
Immunity Relatedreportable segmentsegment profit2020-04-01 → 2021-03-31−¥55m
—segment totalcapex2020-04-01 → 2021-03-31¥13m
—segment totalrevenue2020-04-01 → 2021-03-31¥620m
—segment totalrevenue external2020-04-01 → 2021-03-31¥603m
—segment totalrevenue intersegment2020-04-01 → 2021-03-31¥17m
—segment totalsegment assetsat 2021-03-31¥1.8bn
—segment totalsegment profit2020-04-01 → 2021-03-31−¥242m
—segment totalemployeesat 2022-03-3162 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,233
ItemContextValueUnit
Net assetsPrior1YearInstant_NonConsolidatedMember_ShareholdersEquityMember1843027000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember2166000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1845193000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember_RetainedEarningsBroughtForwardMember-123641000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember_RetainedEarningsMember-123641000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-123641000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember-123641000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember-2166000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember-2166000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_CapitalStockMember－JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_LegalCapitalSurplusMember－JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_CapitalSurplusMember－JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_RetainedEarningsBroughtForwardMember-123641000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_RetainedEarningsMember-123641000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-123641000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember-2166000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember-125807000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_CapitalStockMember3029041000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_LegalCapitalSurplusMember2061421000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_CapitalSurplusMember2061421000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_RetainedEarningsBroughtForwardMember-3369088000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_RetainedEarningsMember-3369088000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-1990000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember1719385000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember－JPY
Net assetsCurrentYearInstant_NonConsolidatedMember1719385000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember66794000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember62132000JPY
Compensations sgaPrior1YearDuration_NonConsolidatedMember27682000JPY
Compensations sgaCurrentYearDuration_NonConsolidatedMember33554000JPY
Supplies expenses sgaPrior1YearDuration_NonConsolidatedMember3694000JPY
Supplies expenses sgaCurrentYearDuration_NonConsolidatedMember1173000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember265611000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember187946000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-06-30
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第40期（自 2021年４月１日 至 2022年３月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社免疫生物研究所
Company name in english cover pageFilingDateInstantImmuno-Biological Laboratories Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長 清藤 勉
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)群馬県藤岡市中字東田1091番地１
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)0274-22-2889（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)常務取締役業務執行責任者兼事業グループ管理本部長 中川 正人
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)群馬県藤岡市中字東田1091番地１
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)0274-22-2889（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)常務取締役業務執行責任者兼事業グループ管理本部長 中川 正人
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00986

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2021-03-31pass
balance sheet identityconsolidated 2022-03-31pass
balance sheet identitynon_consolidated 2021-03-31pass
balance sheet identitynon_consolidated 2022-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2020-03-31pass
statement vs summary · net assetsconsolidated 2021-03-31pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2020-03-31pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2020-04-01/2021-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2020-04-01/2021-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenueconsolidated 2020-04-01/2021-03-31pass
statement vs summary · revenueconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2020-04-01/2021-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · total assetsconsolidated 2021-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2021-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass